Navigation Links
Cambridge Major Appoints Professor John Hartwig as Scientific Advisor
Date:10/31/2007

Expertise in Catalysis and Chiral Chemistry Adds to CML's Technical

Excellence

GERMANTOWN, Wis., Oct. 31 /PRNewswire/ -- Cambridge Major Laboratories announces the appointment of University of Illinois Professor John Hartwig as Scientific Advisor. Professor Hartwig is a world renowned expert in the application of catalysis to the synthesis of amines, halogens, and a variety of chiral transformations. His knowledge will play a vital role in advancing Cambridge Major's development of variety of chemical intermediates and Active Pharmaceutical Ingredients. He joins other prominent academics as part of CML's growing International Scientific Advisory Team.

Professor Hartwig's group has developed a series of catalytic reactions for organic synthesis, including palladium-catalyzed aminations of haloarenes, palladium-catalyzed alpha-arylation of carbonyl compounds, hydroaminations of vinylarenes and dienes, iridium-catalyzed enantioselective allylations of amines and alcohols, and the terminal functionalizations of alkanes. In addition, his group has uncovered new elementary organometallic reactions, such as reductive eliminations of amines, ethers and sulfides, insertions of olefins into transition metal amides and alkoxides, and the oxidative addition of ammonia.

John F. Hartwig received his A.B. from Princeton in 1986 and his Ph.D. from the University of California, Berkeley in 1990. Subsequently, he was an American Cancer Society Postdoctoral Fellow at the Massachusetts Institute of Technology and joined Yale University in 1992 where he was awarded the Irenee P. duPont Professorship in Chemistry in 2004. Dr. Hartwig joined the University of Illinois chemistry faculty in 2006 and currently holds the Kenneth J. Rinehart Jr. Professorship. John Hartwig has received numerous awards including an A.C. Cope Scholar (1998) Award, the Leo Hendrik Baekeland (2003) Award, the Thieme-IUPAC Prize in Synthetic Organic Chemistry (2004), the ACS Award in Organometallic Chemistry (2006), and the Tetrahedron Young Investigator Award in Organic Synthesis (2007).

"It has been a pleasure to become part of the synthetic chemistry community in the midwest, and I am looking forward to working with the experienced and skilled group of synthetic chemists at Cambridge Major Laboratories," said John Hartwig, Kenneth L. Rinehart Jr. Professor of Chemistry, University of Illinois.

"We are excited to have Professor Hartwig join our Scientific Advisory Team. His expertise will significantly help us to expedite synthesis of a wide range of pharmacologically active substances and their key intermediates," said Dr. Michael Major, President and CEO of Cambridge Major. "The addition of Professor Hartwig underscores our commitment to scientific excellence, and also our desire to provide our customers innovative and highly relevant chemistry that works."

Cambridge Major Laboratories, Inc. is a service-based chemistry outsourcing partner to the world's leading pharmaceutical and biotechnology companies, producing pharmaceutical intermediates, Active Pharmaceutical Ingredients, and other organic chemicals. Specializing in chemical process development and advanced multi-step organic synthesis, the Company operates two facilities near Milwaukee, Wisconsin including process chemistry laboratories, kilo labs, pilot plants, and complete analytical laboratories. The Company has been FDA inspected and approved for cGMP manufacturing. Visit us at http://www.c-mlabs.com


'/>"/>
SOURCE Cambridge Major Laboratories
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer
2. Wisconsin building toward the major leagues of venture capital
3. Six things to consider before a major software implementation
4. New company eyes major ethanol production facility
5. Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot
6. University of Michigan plans major stem cell research center
7. BellBrook Labs gets major research funding
8. API announces major healthcare contracts
9. Top 20 big pharmas represent majority of world pharma market
10. Researchers report major advance in gene therapy technique
11. Sharon Ethanol appoints operations director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):